Contineum Therapeutics, Inc.
CTNM · XNASCIK 1855175fmd_1RPJQ4Q8HS7DVFAEVW1FJK73SHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | 50 | 0 | – |
| Research and development | 28 | 38 | 52 |
| Total operating expenses | 34 | 51 | 68 |
| Operating income | 16 | (51) | (68) |
| Interest expense | 0 | 0 | – |
| Interest and investment income | 5 | 9 | 8 |
| Other non-operating income (expense) | 7 | 9 | 8 |
| Income before taxes | 23 | (42) | (60) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | 23 | (42) | (60) |
| Net income | 23 | (42) | (60) |
| Net income to common shareholders | 3 | (42) | – |